Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma by Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen

Subjects: Get full text

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS by Roberta Ottria, Alessandro Ravelli, Matteo Miceli, Sara Casati, Marica Orioli, Pierangela Ciuffreda

Subjects: “…Olaparib…”
Get full text

Profile of olaparib in the treatment of advanced ovarian cancer by Chase DM, Patel S, Shields K

Subjects: “…Olaparib…”
Get full text

Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury by Vanessa Martins, Sidneia S. Santos, Larissa de O. C. P. Rodrigues, Reinaldo Salomao, Lucas Liaudet, Csaba Szabo

Subjects: Get full text

Olaparib-induced pseudoporphyria in a patient with ovarian cancer by Abigale Clark, DO, Amanda S. Weissman, MD, Arthur Neil Crowson, MD, Jason Hirshburg, MD, PhD

Subjects: Get full text

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations by N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, A. S. Makarov

Subjects: Get full text

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland by Jian Pan, Dingwei Ye, Yao Zhu

Subjects: Get full text

Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review by Lina Wahba, Said Nabil, Saba Kendakji, Mariam Ibrahim, Sham ZainAlAbdin, Salahdein Aburuz, Amal Akour

Subjects: “…Olaparib…”
Get full text

BRCA2 reversion mutation confers resistance to olaparib in breast cancer by Shinya Yamamoto, Kei Kawashima, Yoshie Fujiwara, Shoko Adachi, Kazutaka Narui, Chiaki Hosaka, Rina Takahashi, Sho Tsuyuki, Makoto Sugimori, Miki Tanoshima, Mahato Sasamoto, Masanori Oshi, Akimitsu Yamada, Chikara Kunisaki, Itaru Endo

Subjects: Get full text

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer by Soupos Nikolaos, Laschos Konstantinos, Bournakis Evangelos, Kostouros Euthymios, Aravantinos Gerasimos

Subjects: Get full text

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials by Alecu I, Milenkova T, Turner SR

Subjects: Get full text

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer by Hongyu Qin, Jian Zhang, Yilu Zhao, Lihui Zhang, Jinhong Feng, Lei Zhang

Subjects: Get full text

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma by Hye Jeong Park, Jun Sang Bae, Kyoung Min Kim, Young Jae Moon, See-Hyoung Park, Sang Hoon Ha, Usama Khamis Hussein, Zhongkai Zhang, Ho Sung Park, Byung-Hyun Park, Woo Sung Moon, Jung Ryul Kim, Kyu Yun Jang

Subjects: Get full text

Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux by Ruixue Liu, Fengjuan Li, Shuai Hao, Dongyao Hou, Xue Zeng, He Huang, Gautam Sethi, Jun Guo, Chenyang Duan

Subjects: Get full text

Investigation of Stabilized Amorphous Solid Dispersions to Improve Oral Olaparib Absorption by Taehan Yun, Sumin Lee, Seowan Yun, Daeyeong Cho, Kyuho Bang, Kyeongsoo Kim

Subjects: “…olaparib…”
Get full text

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy by Toko Kumeta, Ryoichi Matsunuma, Kei Yamaguchi, Ryosuke Hayami, Michiko Tsuneizumi

Subjects: “…olaparib…”
Get full text

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer by Wu M, Liu J, Hu C, Li D, Yang J, Wu Z, Yang L, Chen Y, Fu S, Wu J

Subjects: Get full text

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial by Dean A. Fennell, Catharine Porter, Jason Lester, Sarah Danson, Fiona Blackhall, Marianne Nicolson, Lisette Nixon, Georgina Gardner, Ann White, Gareth Griffiths, Angela Casbard

Subjects: Get full text

TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC by Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang

Subjects: Get full text

Ovarian cancer molecular stratification and tumour heterogeneity; a necessity and a challenge by Stefan eSymeonides, Charlie eGourley

Subjects: Get full text